Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
13 September 2024 - 10:35PM
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic
company focused on developing products to treat cancer and
life-threatening infectious diseases, is pleased to announce that
Jim Frakes, interim CEO and CFO and Steve LaRosa, Chief Medical
Officer, will present live at the Life Sciences Investor Forum,
hosted by VirtualInvestorConferences.com, on September 19th 2024.
DATE: September 19th TIME: 1:30 PM
ETLINK: https://bit.ly/3XjDJkLAvailable
for 1x1 meetings: September 19 and 20.
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
It is recommended that online investors pre-register and run the
online system check to expedite participation and receive event
updates.
Learn more about the event at
www.virtualinvestorconferences.com.
About Aethlon and the
Hemopurifier®Aethlon Medical is a medical
therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat
cancer and life-threatening viral infections and for use in organ
transplantation. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and in
pre-clinical studies, the Hemopurifier has demonstrated the removal
of harmful exosomes from biological fluids, utilizing its
proprietary lectin-based technology. This action has potential
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases. The Hemopurifier is a U.S. Food and Drug Administration
(FDA) designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found
at www.AethlonMedical.com.
About Virtual Investor Conferences®Virtual
Investor Conferences (VIC) is the leading proprietary investor
conference series that provides an interactive forum for publicly
traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is
specifically designed to offer companies more efficient investor
access. Replicating the components of an on-site investor
conference, VIC offers companies enhanced capabilities to connect
with investors, schedule targeted one-on-one meetings and enhance
their presentations with dynamic video content. Accelerating the
next level of investor engagement, Virtual Investor Conferences
delivers leading investor communications to a global network of
retail and institutional investors.
Company Contact:Jim FrakesInterim Chief
Executive Officer and Chief Financial OfficerAethlon Medical,
Inc.Jfrakes@aethlonmedical.com
Investor Contact:Susan NoonanS.A. Noonan
Communications, LLCsusan@sanoonan.com
Virtual Investor Conferences John M.
ViglottiSVP Corporate Services, Investor AccessOTC Markets Group
(212) 220-2221johnv@otcmarkets.com
Aethlon Medical (NASDAQ:AEMD)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aethlon Medical (NASDAQ:AEMD)
Historical Stock Chart
From Oct 2023 to Oct 2024